Member Info for Silverblade

The clinical story is not the issue here. It’s the inability to commercialise the product which is reflected in the ongoing multi year slump. SB

For the sake of shareholders please stop this buyback madness which is having the completely opposite effect intended…..SB

Don't disagree with anything you say Guitarsolo - but the entire UK PLC infra sector is currently is meltdown and the HICL/TRIG announcement is the latest attempt to stem the flow of capital from the sector (driven by a bit of self interest from the investment managers). There is certainty an appetite for infra asset purchases from pensions funds - BBGI as you noted - and also recently Royal London picked up privately owned Dalmore Capital which managed a £6 billion infrastructure portfolio including the Thames Tideway Tunnel, 24 operational wind farms in the UK with total capacity of 562MW, and significant PPP/PFI assets.

Royal London, commented: "Royal London is the personal pension provider most recommended by Independent Financial Advisers*. By acquiring Dalmore Capital, we can offer our individual and workplace pension savers access to the long-term, stable returns that infrastructure investments can potentially provide. Additionally, it demonstrates our commitment to invest in assets that support the UK’s drive for economic growth and an innovative, sustainable future."

INPP is certainly one of the few remaining infra funds with operational scale, longevity, investment pipeline and inflation linked cash flows. SB

I'm not sure it can go much lower appleby - at 70p its a 10% yield - with a 30% discount to its NAV. I'm hopeful we will get an update on asset realisations by end of the year. SB

Looks like the HICL/TRIG merger (it it goes ahead after significant shareholder backlash) is causing sector wide collateral damage with NAV discounts increasing. Worries on how gilts react to next weeks budget won't help. Meanwhile INPP has now hoovered up 90m+ shares in its buyback programme, has demonstrated portfolio value through selected asset realisations and continues to make investments. Cash rich pension funds looking for inflation linked assets must be looking into opportunities here you would think. SB

There you go donmac almost at your buy price already. SB

I'm not a fan to date either fevertree - its been a disaster for all shareholders here - but I still hold a position here and am trying to look forward not back given the past is what it is. If Q4 goes well I expect a trading update early 2026 - which doesn't usually happen but positive momentum will be required to avoid a total wipe out in any subsequent capital raise. Failure to deliver (again) then more questions will be raised on leadership competencies. SB

Based on what we already know - VRCI sold c.600 Tutivia tests in H1 2025 - securing revenue of $1.2m ($2k per test - blend of public and private payers). They sold same in Q3 - so lets assume pro-rata they secured a further $600k revenue. Sara B confirmed FY Tutivia target was $3.2m - so that leaves $1.4 revenue to be secured in Q4 - or c.700 tests at $2k. Seems a huge leap - or possible they are looking at a slight increase to average test $ - although Prime Health RNS appears to push towards discounted volume in private market. She has certainly set high expectations for Q4 trading. If this is achieved it will be a significant acceleration - and will be crucial in supporting the share price/market cap as the company requires additional funding in the next 4/5 months. Additional licensing revenue from Thermo (c.$4m received to date - $3.3m in 2024 and $0.75m in 2025) remains on hold as they progress their approach to the PTRA test. SB

There is such uncertainty about the budget and wider geo-political issues its negatively impacting just about every stock I own. SRC continues to show real momentum in its strategic growth model - achieving ebitda of £250m+ for FY 2025 would be stellar and is very achievable. Anything around this price level looks good long term to me. SB

Not sure I like GCPs attempt to close its NAV discount by continuously reducing the value of its assets. Equity exposure continues to hurt any hope of a recovery here. SB

Same again today. We all got mugged by the Renx story. IIs and PIs alike - everyone gets burned here. There is just no appetite for the product which is a great shame given its potential positive impact on CKD. SB

The amount of shareholder value destroyed by Julian Baines and Christopher Mills in EKF, RENX and VRCI is quite incredible. For EKF to be trading where it is given its cash, ebitda and market opportunity reflects the general consensus that the business is just going nowhere under current ownership and leadership. It should be put up for sale. SB

Mikodx - I'm not going to get into a debate on whether vrci or renx has the better product - they are both kidney test spin outs from EKF which use unique biomarkers to assist patient care. I simply pointed out the need to be accurate when commenting on revenue. Vrci H1 2025 was $1.9m - standing still they will achieve $4m FY. They chose to secure Medicare coverage for their test via an alternative route to FDA - but their approval under an approved Medicare contractor and reimbursement at $2650 per test is equally valid in the market. SB

Mikodx - Vrci revenue for its lead kidney product is targeted at $3.2m this year - more than Renxs $3m. Plus they have $0.75m additional licensing revenue. If you quote numbers get them correct. SB

FY 2025 total revenue was $3m. Q1 Revenue $0.52m. Q2 Revenue $0.78m. Q3 Revenue $0.94m (based on 20% QoQ growth). So that implies Q4 Revenue c. $0.76m. Now do you see why price is heading south. They simply cannot get any sales traction. SB

Eh no Marty. The share price is collapsing because sales are in decline, all the strategic partnership announcements have had no impact on revenue, the chairman has served notice after false promises, fund raising has created massive oversupply of shares, the bare bones RNS yesterday with no current trading update (and the gloomy implications as a result) has completely spooked the market - and cash burn is still crazy high for a business selling 60 of its FDA approved wonder diagnostic tests a week......car crash. Again. SB

The only thing the Renx continually delivers is disappointment. We have all been mugged by McCullough again - including a new slug of institutional investors and all the PIs who got caught up in the Tempus nonsense. Even Baines is giving up. You would think we would all learn!! SB

FY revenue as previously flagged. Costs higher, losses greater. Q4 saw a decline in testing revenue despite assurances from the now departing exec chairman growth was firmly being achieved. There is a pattern here - announce new partnership; secure funding with hundreds of millions of new shares ; create shareholder interest; publish disappointing results with no income from previously announced partnerships, rinse and repeat. 4 months into 2026 trading year - not a word on current trading. Not a word on previously announced revenue targets for 2026; 2027 and 2028. Reference to a capital markets day in Q3 2026 - jolly good lads. Welcome to Renalytix......SB

Dividend announced but no NAV update. Strange? SB

Greencoat UK wind (UKW) announced NAV hit this morning which has spooked sector. Hard to think we won’t see similar from GCP tomorrow. SB